Clinical trial
A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)
NCT06271512 is registered in ClinicalTrials.gov with Genetix Biotherapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- January 23, 2024
- Completion date
- December 31, 2043
- Enrollment
- 150 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.